New hope for tough cancers: revumenib trial shows promise

NCT ID NCT05731947

Completed Disease control Sponsor: Syndax Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tested the drug revumenib in 42 adults with colorectal cancer or other solid tumors that had spread or come back after at least one prior treatment. The goal was to see if the drug is safe and can slow tumor growth. Researchers measured side effects, how the drug moves through the body, and how well it controlled the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLORECTAL CANCER SOLID TUMORS

Contacts and locations

Show contact details

Locations

Gabrail Cancer Center

Canton, Ohio, 44718, United States
Honor Health Research Institute

Scottsdale, Arizona, 85258, United States
Inova Schar Cancer Institute

Fairfax, Virginia, 22031, United States
Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
Memorial Sloan Kettering Cancer Center

Manhattan, New York, 10065, United States
Vanderbilt-Ingram Cancer Center

Nashville, Tennessee, 37232, United States